Birgitte Klindt Poulsen chairs Medicinrådet, the council that decides which new hospital medicines Denmark's regions take into standard use.
Birgitte Klindt Poulsen is named as forperson (chair) of Medicinrådet in its 2026 announcements. Commenting on the recommendation of the CAR-T therapy brexucabtagene autoleucel under an outcome-based risk-sharing agreement, she said that the treatment is very expensive and its effect uncertain, and that the agreement lets the health service use it and collect data on its effect in Danish practice; on trastuzumab deruxtecan she said the council would like to see more such agreements.
Shares Medicinrådet (Danish Medicines Council) and the tag government.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/